menu
    • menu

    Company profile for Tetra Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Tetra Therapeutics, a clinical-stage biopharmaceutical company developing novel treatments for patients with cognitive impairment and memory loss, today announced it has entered into an expanded strategic alliance with Shionogi. The two companies will work together to develop and commercialize BPN14770 for the treatment of Alzheimer’s disease, Fragile X syndrome and other indications marked by cognitive and memory deficits. ...
    Tetra Therapeutics, a clinical-stage biopharmaceutical company developing novel treatments for patients with cognitive impairment and memory loss, today announced it has entered into an expanded strategic alliance with Shionogi. The two companies will work together to develop and commercialize BPN14770 for the treatment of Alzheimer’s disease, Fragile X syndrome and other indications marked by cognitive and memory deficits. Under the terms of the expanded alliance, Shionogi has increased its equity investment in the company to

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Tetra TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2220 Wealthy Street SE Grand Rapids MI 49506
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://tetratherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tetra Tx Initiates PIIb/III Studies of BPN14770 in Fragile X Syndrome
    Tetra Tx Initiates PIIb/III Studies of BPN14770 in Fragile X Syndrome

    12 Jul 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220712005003/en

    BUSINESSWIRE
    12 Jul 2022
    Share Share
    Tetra Therapeutics Announces Retirement of Mark Gurney
    Tetra Therapeutics Announces Retirement of Mark Gurney

    23 Jul 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210723005075/en

    BUSINESSWIRE
    23 Jul 2021
    Share Share
    Tetra Announces Positive Topline Results from Phase 2 Study of BPN14770
    Tetra Announces Positive Topline Results from Phase 2 Study of BPN14770

    02 Nov 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201102005309/en

    BUSINESSWIRE
    02 Nov 2020
    Share Share
    Tetra Announces Positive Topline Results from Phase 2 Study of BPN14770
    Tetra Announces Positive Topline Results from Phase 2 Study of BPN14770

    02 Nov 2020

    // BIOSPACE

    https://www.biospace.com/article/releases/tetra-therapeutics-announces-positive-topline-results-from-phase-2-study-of-bpn14770-in-patients-with-fragile-x-syndrome/

    BIOSPACE
    02 Nov 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search